Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Than 'That Old Shkreli Co.,' KaloBios Ready To Innovate, Change Biotech

Executive Summary

KaloBios Pharmaceuticals Inc. is now free of Martin Shkreli, after the pharma 'bad boy' sold his remaining stock, and wants to get on with its work of focusing on R&D of medicines that benefit patients with rare and neglected diseases. But the firm also has some ideas it thinks could change biotech.

Advertisement

Related Content

Bridging The Drug Price Divide: Ideas And Approaches Debated At PSA
Allergan's Price Reform Pledge: Will Others Follow?
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
KaloBios Rises From Bankruptcy Ashes With PRV Still Firmly In Its Sights
Shkreli's Empire Collapses: KaloBios Seeks Bankruptcy Protection
KaloBios Seeks Appeal Of Nasdaq Delisting
Shkreli's Ponzi Scheme Trifecta: Lies, Deceit And Greed
Shkreli Arrested On Securities Fraud; KaloBios Hit Hard

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel